Arcellx Earnings Call Transcripts
Fiscal Year 2025
-
Anito-cel shows high efficacy, durable responses, and a favorable safety profile, setting it apart from other CAR T and bispecific therapies. With strong clinical trial results, imminent BLA submission, and robust commercial readiness, it is positioned for broad adoption and potential market expansion.
-
Anito-cel continues to show strong efficacy and a differentiated safety profile in late-line multiple myeloma, with no delayed neurotoxicity observed and high MRD negativity rates. Regulatory and commercial plans remain on track for a 2026 launch, with expansion into earlier lines and additional pipeline progress ongoing.
-
Anito-cel is positioned to lead the myeloma CAR T market with strong efficacy, a highly differentiated safety profile, and rapid, scalable manufacturing through its Kite partnership. Physician and patient research support broad adoption, especially in community and frail patient populations, with commercial launch targeted for mid-to-late 2026.
-
iMMagine-1 trial data for anito-cel show strong efficacy and a differentiated safety profile, with no delayed neurotoxicity observed and manufacturing readiness for launch. Regulatory filings are on track for a mid-to-late 2026 launch, with priority review expected.
-
Anito-cel is positioned as a best-in-class BCMA therapy for multiple myeloma, showing strong efficacy and a differentiated safety profile with no delayed neurotoxicities in over 155 patients. Manufacturing and access advantages, a robust pipeline, and a favorable partnership with Kite-Gilead support a 2026 launch and long-term growth.
Fiscal Year 2024
-
Anito-cel demonstrated high response rates, deep MRD negativity, and a favorable safety profile with minimal neurotoxicity in relapsed/refractory myeloma. Manufacturing is highly reliable, and broad access is supported by Kite's infrastructure. Physicians expect rapid adoption and increased outpatient use.